193 related articles for article (PubMed ID: 37127471)
21. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma.
Gaballa MR; Ma J; Rauf M; Bassett R; Pasvolsky O; Tanner MR; Bashir Q; Srour SA; Saini N; Ramdial J; Nieto Y; Murphy R; Rezvani K; Tang G; Lin P; Lee HC; Patel KK; Ullah MR; Kaufman GP; Manasanch EE; Kebriaei P; Thomas SK; Weber DM; Shpall EJ; Champlin RE; Orlowski RZ; Qazilbash MH
Bone Marrow Transplant; 2022 Jul; 57(7):1142-1149. PubMed ID: 35523847
[TBL] [Abstract][Full Text] [Related]
22. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
Landgren O; Hultcrantz M; Diamond B; Lesokhin AM; Mailankody S; Hassoun H; Tan C; Shah UA; Lu SX; Salcedo M; Werner K; Rispoli J; Caple J; Sams A; Verducci D; Jones K; Concepcion I; Ciardello A; Chansakul A; Schlossman J; Tavitian E; Shekarkhand T; Harrison A; Piacentini C; Rustad EH; Yellapantula V; Maclaughlan K; Maura F; Landau HJ; Scordo M; Chung DJ; Shah G; Lahoud OB; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Derkach A; Giralt SA; Korde N
JAMA Oncol; 2021 Jun; 7(6):862-868. PubMed ID: 33856405
[TBL] [Abstract][Full Text] [Related]
23. Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.
Morabito F; Zamagni E; Conticello C; Pavone V; Palmieri S; Bringhen S; Galli M; Mangiacavalli S; Derudas D; Rossi E; Ria R; Catalano L; Tacchetti P; Mele G; Vincelli ID; Martino EA; Vigna E; Bruzzese A; Mendicino F; Botta C; Mele A; Pantani L; Rocchi S; Garibaldi B; Cascavilla N; Ballanti S; Tripepi G; Frigeri F; Falcone AP; Cangialosi C; Reddiconto G; Farina G; Barone M; Rizzello I; Iaccino E; Mimmi S; Curci P; Gamberi B; Musto P; De Stefano V; Musso M; Petrucci MT; Offidani M; Di Raimondo F; Boccadoro M; Cavo M; Neri A; Gentile M
Front Oncol; 2022; 12():890376. PubMed ID: 35924160
[TBL] [Abstract][Full Text] [Related]
24. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma.
Pasvolsky O; Ghanem S; Milton DR; Masood A; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Transplant Cell Ther; 2023 Dec; 29(12):757-762. PubMed ID: 37673125
[TBL] [Abstract][Full Text] [Related]
26. Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis.
Mangiacavalli S; Cartia CS; Galli M; Pezzatti S; Belotti A; Fazio F; Mina R; Marcatti M; Cafro A; Zambello R; Paris L; Barilà G; Olivares C; Pompa A; Mazza R; Farina F; Soldarini M; Benvenuti P; Pagani G; Palumbo M; Masoni V; Ferretti VV; Klersy C; Arcaini L; Petrucci MT
Haematologica; 2023 Mar; 108(3):833-842. PubMed ID: 36200419
[TBL] [Abstract][Full Text] [Related]
27. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
Mateos MV; Goldschmidt H; San-Miguel J; Mikhael J; DeCosta L; Zhou L; Obreja M; Blaedel J; Szabo Z; Leleu X
Hematol Oncol; 2018 Apr; 36(2):463-470. PubMed ID: 29446103
[TBL] [Abstract][Full Text] [Related]
28. Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.
Montefusco V; Corso A; Galli M; Ardoino I; Pezzatti S; Carniti C; Patriarca F; Gherlinzoni F; Zambello R; Sammassimo S; Marcatti M; Nozza A; Crippa C; Cafro AM; Baldini L; Corradini P
Br J Haematol; 2020 Mar; 188(6):907-917. PubMed ID: 31898319
[TBL] [Abstract][Full Text] [Related]
29. Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial.
Lee JH; Park Y; Kang KW; Lee JJ; Lee HS; Eom HS; Do YR; Kim JS; Yoon SS; Shin DY; Koh Y; Kim KH; Lee WS; Jo JC; Lee YJ; Lee JY; Kim DS; Shim H; Chang MH; Kim SH; Min CK;
Ann Hematol; 2021 Aug; 100(8):2051-2059. PubMed ID: 33447888
[TBL] [Abstract][Full Text] [Related]
30. Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.
Steinmetz HT; Singh M; Lebioda A; Gonzalez-McQuire S; Rieth A; Schoehl M; Poenisch W
Oncol Res Treat; 2020; 43(9):449-459. PubMed ID: 32694243
[TBL] [Abstract][Full Text] [Related]
31. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Jasielec JK; Kubicki T; Raje N; Vij R; Reece D; Berdeja J; Derman BA; Rosenbaum CA; Richardson P; Gurbuxani S; Major S; Wolfe B; Stefka AT; Stephens L; Tinari KM; Hycner T; Rojek AE; Dytfeld D; Griffith KA; Zimmerman TM; Jakubowiak AJ
Blood; 2020 Nov; 136(22):2513-2523. PubMed ID: 32735641
[TBL] [Abstract][Full Text] [Related]
32. Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan.
Suzuki K; Ri M; Chou T; Sugiura I; Takezako N; Sunami K; Ishida T; Izumi T; Ozaki S; Shumiya Y; Ota K; Iida S
Cancer Sci; 2017 Mar; 108(3):461-468. PubMed ID: 28092421
[TBL] [Abstract][Full Text] [Related]
33. Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
DerSarkissian M; Cranmer H; Dabora J; Bocharova I; Cherepanov D; Cheng M; Bhak RH; Duh MS
Hematology; 2023 Dec; 28(1):2156731. PubMed ID: 36607147
[TBL] [Abstract][Full Text] [Related]
34. Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data.
Campioni M; Agirrezabal I; Hajek R; Minarik J; Pour L; Spicka I; Gonzalez-McQuire S; Jandova P; Maisnar V
Eur J Health Econ; 2020 Mar; 21(2):219-233. PubMed ID: 31673898
[TBL] [Abstract][Full Text] [Related]
35. Real-world outcomes for the treatment of relapsed/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from
Duarte PJ; Schutz NP; Ochoa P; Yantorno S; Orlando S; Lopresti S; Zabaljauregui S; Aizpurua F; Shanley C; Giannini E; Garate G; Foncuberta C; Milone J; Riveros D; Fantl D
Expert Rev Hematol; 2021 Mar; 14(3):315-322. PubMed ID: 33541156
[TBL] [Abstract][Full Text] [Related]
36. Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
Jakubowiak A; Usmani SZ; Krishnan A; Lonial S; Comenzo RL; Wang J; de Boer C; Deraedt W; Weiss BM; Schecter JM; Chari A
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):701-710. PubMed ID: 34274290
[TBL] [Abstract][Full Text] [Related]
37. Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers.
Hose D; Schreder M; Hefner J; Bittrich M; Danhof S; Strifler S; Krauth MT; Schoder R; Gisslinger B; Einsele H; Gisslinger H; Knop S
J Cancer Res Clin Oncol; 2021 Jan; 147(1):205-212. PubMed ID: 32683487
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed multiple myeloma: A systematic review and meta-analysis.
Costa BA; Costa TA; Pak K; Patel A; Felix N; Mouhieddine TH; Richter J
Am J Hematol; 2024 Jul; 99(7):1411-1414. PubMed ID: 38606993
[TBL] [Abstract][Full Text] [Related]
39. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
40. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.
Costa LJ; Chhabra S; Medvedova E; Dholaria BR; Schmidt TM; Godby KN; Silbermann R; Dhakal B; Bal S; Giri S; D'Souza A; Hall A; Hardwick P; Omel J; Cornell RF; Hari P; Callander NS
J Clin Oncol; 2022 Sep; 40(25):2901-2912. PubMed ID: 34898239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
